Literature DB >> 17986167

Nerve stimulator-guided repetitive paravertebral block for thoracic myofascial pain syndrome.

Zoher M Naja1, Mohamad A Al-Tannir, Ahed Zeidan, Mariam El-Rajab, Fouad Ziade, Anis Baraka.   

Abstract

Myofascial pain syndrome (MPS) may persist for many years and is often refractory to traditional therapeutic approaches including pharmacotherapy, focal tenderness infiltration by local anesthetic and corticosteroids, physical therapy and behavioral modification. This report describes three cases of MPS following coronary artery bypass graft, inadequate positioning during abdominal hysterectomy, and excessive physical effort refractory to conventional therapeutic approaches. Three patients were successfully treated with repeated nerve stimulator-guided paravertebral block using a mixture of bupivacaine and clonidine. Physical examinations including a complete neurological assessments were unremarkable. Relevant diagnostic imaging (X-ray, magnetic resonance imaging, computed tomography) and laboratory evaluations also failed to demonstrate any significant structural disorders or systemic diseases that might have been responsible for their pain. Nerve stimulator-guided paravertebral block was performed at the dermatomes corresponding to the thoracic myofascial pain region. Each point was injected with 4 mL of the local anesthetic solution. If the pain returned, a second paravertebral block was performed. The three patients were pain-free over a follow-up period up to 2 years. Our report suggests that nerve stimulator-guided paravertebral blockade could be a useful treatment for MPS refractory to traditional therapeutic approaches.

Entities:  

Mesh:

Year:  2007        PMID: 17986167     DOI: 10.1111/j.1533-2500.2007.00149.x

Source DB:  PubMed          Journal:  Pain Pract        ISSN: 1530-7085            Impact factor:   3.183


  1 in total

1.  Implantation of an intercostal nerve stimulator for chronic abdominal pain.

Authors:  R D Johnson; A L Green; T Z Aziz
Journal:  Ann R Coll Surg Engl       Date:  2010-04       Impact factor: 1.891

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.